PE20021083A1 - MODULATORS OF THE ESTROGEN RECEPTORS - Google Patents
MODULATORS OF THE ESTROGEN RECEPTORSInfo
- Publication number
- PE20021083A1 PE20021083A1 PE2002000308A PE2002000308A PE20021083A1 PE 20021083 A1 PE20021083 A1 PE 20021083A1 PE 2002000308 A PE2002000308 A PE 2002000308A PE 2002000308 A PE2002000308 A PE 2002000308A PE 20021083 A1 PE20021083 A1 PE 20021083A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- alkenyl
- modulators
- acetophenone
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title abstract 2
- 108010038795 estrogen receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 229940073735 4-hydroxy acetophenone Drugs 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
- C07D339/08—Six-membered rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, OR6, ENTRE OTROS; R2 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R3 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R4 ES H, ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ALQUINILO C2-C5, ENTRE OTROS; R5 ES ALQUILO C1-C5, CICLOALQUILO C3-C8, ALQUENILO C2-C5, ENTRE OTROS; X E Y SON O, S, SULFOXIDO, SULFONA; R6 ES H, ALQUILO C1-C5, BENCILO, METOXIMETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-TIOFENO-4-METOXI-ACETOFENONA, 2-TIOFENO-4-HIDROXI-ACETOFENONA, 2-TIOFENO-4-METOXI-ACETOFENONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON MODULADORES DE LOS RECEPTORES ESTROGENOS Y SON UTILES PARA EL TRATAMIENTO DE OSTEOPOROSIS, DEGENERACION DE CARTILAGO, ENDOMETRIOSISREFERS TO COMPOUNDS OF FORMULA I WHERE R1 IS H, C1-C5 ALKYL, C3-C8 CYCLOALKYL, C2-C5 ALKENYL, C2-C5 ALKYNYL, OR6, AMONG OTHERS; R2 IS H, C1-C5 ALKYL, C3-C8 CYCLOALKYL, C2-C5 ALKENYL, C2-C5 ALKYL, AMONG OTHERS; R3 IS H, C1-C5 ALKYL, C3-C8 CYCLOALKYL, C2-C5 ALKENYL, C2-C5 ALKYL, AMONG OTHERS; R4 IS H, C1-C5 ALKYL, C3-C8 CYCLOALKYL, C2-C5 ALKENYL, C2-C5 ALKYL, AMONG OTHERS; R5 IS C1-C5 ALKYL, C3-C8 CYCLOALKYL, C2-C5 ALKYL, AMONG OTHERS; X AND Y ARE O, S, SULFOXIDE, SULFONE; R6 IS H, C1-C5 ALKYL, BENZYL, METOXIMETHYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE 2-THIOPHENE-4-METOXY-ACETOPHENONE, 2-THIOPHENE-4-HYDROXY-ACETOPHENONE, 2-THIOPHENE-4-METOXY-ACETOPHENONE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PROCEDURE FOR THE PREPARATION. THE MENTIONED COMPOUNDS ARE MODULATORS OF THE ESTROGEN RECEPTORS AND ARE USEFUL FOR THE TREATMENT OF OSTEOPOROSIS, CARTILAGE DEGENERATION, ENDOMETRIOSIS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24158200P | 2000-10-19 | 2000-10-19 | |
| PCT/US2001/042735 WO2002032377A2 (en) | 2000-10-19 | 2001-10-15 | Estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021083A1 true PE20021083A1 (en) | 2002-12-16 |
Family
ID=22911282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000308A PE20021083A1 (en) | 2000-10-19 | 2002-04-15 | MODULATORS OF THE ESTROGEN RECEPTORS |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1333827A2 (en) |
| JP (1) | JP2004511502A (en) |
| KR (1) | KR20030042020A (en) |
| CN (1) | CN1469743A (en) |
| AU (2) | AU3238102A (en) |
| BG (1) | BG107676A (en) |
| BR (1) | BR0114689A (en) |
| CA (1) | CA2424729A1 (en) |
| EA (1) | EA200300474A1 (en) |
| EC (1) | ECSP034558A (en) |
| EE (1) | EE200300153A (en) |
| HU (1) | HUP0303563A2 (en) |
| IL (1) | IL154984A0 (en) |
| IS (1) | IS6761A (en) |
| MX (1) | MXPA03003485A (en) |
| NO (1) | NO20031737L (en) |
| PE (1) | PE20021083A1 (en) |
| PL (1) | PL361053A1 (en) |
| SK (1) | SK4772003A3 (en) |
| WO (1) | WO2002032377A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030225132A1 (en) * | 2002-04-11 | 2003-12-04 | Dininno Frank P. | Estrogen receptor modulators |
| US7138426B2 (en) * | 2002-04-24 | 2006-11-21 | Merck & Co., Inc. | Estrogen receptor modulators |
| RU2387451C2 (en) | 2002-05-10 | 2010-04-27 | Ф.Хоффманн-Ля Рош Аг | Bisphosphonic acids intended for treatment and prevention of osteoporosis |
| CA2512000C (en) * | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| EP2314295B1 (en) * | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
| CN101641339B (en) | 2007-02-01 | 2013-07-17 | 雷斯韦洛吉克斯公司 | Compounds for the prevention and treatment of cardiovascular diseases |
| US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| AU2010224523B2 (en) | 2009-03-18 | 2014-05-08 | Resverlogix Corp. | Novel anti-inflammatory agents |
| MX374414B (en) | 2009-04-22 | 2025-03-06 | Resverlogix Corp | NEW ANTI-INFLAMMATORY AGENTS. |
| EP2580210B1 (en) | 2010-06-10 | 2017-03-01 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| SI2773354T1 (en) | 2011-11-01 | 2019-08-30 | Resverlogix Corp. | Oral immediate release formulations for substituted quinazolinones |
| EP2791132A4 (en) | 2011-12-14 | 2015-08-05 | Seragon Pharmaceuticals Inc | MODULATORS OF STROGEN RECEPTORS AND USES THEREOF |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| CN105073744B (en) | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | Novel heterocyclic compounds as bromodomain inhibitors |
| CN107530356A (en) | 2015-03-13 | 2018-01-02 | 雷斯韦洛吉克斯公司 | Compositions and methods of treatment for treating complement-associated diseases |
-
2001
- 2001-10-15 CA CA002424729A patent/CA2424729A1/en not_active Abandoned
- 2001-10-15 SK SK477-2003A patent/SK4772003A3/en unknown
- 2001-10-15 WO PCT/US2001/042735 patent/WO2002032377A2/en not_active Ceased
- 2001-10-15 KR KR10-2003-7005518A patent/KR20030042020A/en not_active Withdrawn
- 2001-10-15 AU AU3238102A patent/AU3238102A/en active Pending
- 2001-10-15 CN CNA018176720A patent/CN1469743A/en active Pending
- 2001-10-15 JP JP2002535616A patent/JP2004511502A/en not_active Withdrawn
- 2001-10-15 EE EEP200300153A patent/EE200300153A/en unknown
- 2001-10-15 HU HU0303563A patent/HUP0303563A2/en unknown
- 2001-10-15 EA EA200300474A patent/EA200300474A1/en unknown
- 2001-10-15 EP EP01987654A patent/EP1333827A2/en not_active Withdrawn
- 2001-10-15 MX MXPA03003485A patent/MXPA03003485A/en unknown
- 2001-10-15 BR BR0114689-0A patent/BR0114689A/en not_active Application Discontinuation
- 2001-10-15 AU AU2002232381A patent/AU2002232381B2/en not_active Ceased
- 2001-10-15 IL IL15498401A patent/IL154984A0/en unknown
- 2001-10-15 PL PL01361053A patent/PL361053A1/en not_active Application Discontinuation
-
2002
- 2002-04-15 PE PE2002000308A patent/PE20021083A1/en not_active Application Discontinuation
-
2003
- 2003-03-26 BG BG107676A patent/BG107676A/en unknown
- 2003-03-27 IS IS6761A patent/IS6761A/en unknown
- 2003-04-15 NO NO20031737A patent/NO20031737L/en unknown
- 2003-04-17 EC EC2003004558A patent/ECSP034558A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP034558A (en) | 2003-06-25 |
| EA200300474A1 (en) | 2003-10-30 |
| SK4772003A3 (en) | 2003-08-05 |
| JP2004511502A (en) | 2004-04-15 |
| EE200300153A (en) | 2003-06-16 |
| KR20030042020A (en) | 2003-05-27 |
| WO2002032377A3 (en) | 2002-08-22 |
| CN1469743A (en) | 2004-01-21 |
| IS6761A (en) | 2003-03-27 |
| WO2002032377A2 (en) | 2002-04-25 |
| BR0114689A (en) | 2003-07-01 |
| AU3238102A (en) | 2002-04-29 |
| PL361053A1 (en) | 2004-09-20 |
| HUP0303563A2 (en) | 2004-03-01 |
| BG107676A (en) | 2003-11-28 |
| EP1333827A2 (en) | 2003-08-13 |
| IL154984A0 (en) | 2003-10-31 |
| NO20031737D0 (en) | 2003-04-15 |
| CA2424729A1 (en) | 2002-04-25 |
| AU2002232381B2 (en) | 2004-11-18 |
| MXPA03003485A (en) | 2003-07-14 |
| NO20031737L (en) | 2003-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021083A1 (en) | MODULATORS OF THE ESTROGEN RECEPTORS | |
| PE20060401A1 (en) | DERIVATIVES OF N- (2-BENZYL) -2-PHENYL-BUTANAMIDES AND PROPANAMIDES AS MODULATORS OF THE ANDROGEN RECEPTOR | |
| CR8753A (en) | DERIVATIVES OF TETRAAZABENZO [E] AZULENO AND ITS ANALOGS | |
| CY1106486T1 (en) | METHOD OF PREPARING 2-(QUINOXALIN-5-YLSULFONYLAMINO) BENZAMIDE COMPOUNDS | |
| PE69299A1 (en) | CALCILITICAL COMPOUNDS | |
| PE20030601A1 (en) | DERIVATIVES OF 1,8-NAPHTHYRIDINE AND THEIR USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | |
| ES2180981T3 (en) | PROCEDURE FOR THE PREPARATION OF A MAGNESIUM SALT OF A SUBSTITUTED SULFINYL HETEROCICLE. | |
| PE20061084A1 (en) | 2-CYANE-3- (HALO) ALCOXY-BENZENOSULFONAMIDE DERIVED COMPOUNDS | |
| NO20041504L (en) | Lactam derivatives as antagonists of human 11CBY receptors. | |
| EA200970326A1 (en) | ALKYL DERIVATIVES AS METABOTROPIC GLUTAMAT RECEPTORS | |
| ATE496620T1 (en) | 1H-BENZO(F)INDAZOLE-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | |
| ECSP034744A (en) | N-REPLACED N-REPLACED NMDA / NR2B ANTAGONISTS | |
| DK1408961T3 (en) | 2 pyrrolidone derivatives as prostanoid agonists | |
| PE20030471A1 (en) | IMIDAZOPIRIDIN COMPOUND AS 5-HT4 RECEIVER MODULATORS | |
| AR057981A1 (en) | PIRROLOQUINOLIN COMPOUND -4- ONA, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND INTERMEDIATE COMPOUNDS FOR ITS PREPARATION | |
| PE20061106A1 (en) | DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE | |
| ATE303369T1 (en) | GLUCOCORTICOID RECEPTOR MODULATORS | |
| PE20040678A1 (en) | MODULATORS OF SELECTIVE ESTROGEN RECEPTORS | |
| PE20051054A1 (en) | HETEROCYCLIC COMPOUNDS USEFUL AS SECRETAGOGS OF GROWTH HORMONE | |
| AR058587A1 (en) | PIRROLO-1,5-NAFTIRIDINONE COMPOUNDS, ITS USE AS ANTIBACTERIAL AGENTS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND INTERMEDIARY COMPOUNDS TO PREPARE SUCH COMPOUNDS | |
| PE20060610A1 (en) | TETRACYCLIC DERIVATIVES AS MODULATORS OF ESTROGEN RECEPTORS | |
| PE20060590A1 (en) | 15ß-SUBSTITUTED STEROIDAL COMPOUNDS WITH SELECTIVE ACTIVITY OF THE ESTROGEN RECEPTOR | |
| PA8568101A1 (en) | INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE | |
| EA200600694A1 (en) | DISULPHID, SULPHIDE, SULPHOXIDE AND SULPHONE DERIVATIVES OF CYCLIC SUGARS AND THEIR APPLICATION | |
| PA8475401A1 (en) | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |